Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy

The B-cell receptor signaling pathway is active in diffuse large B-cell lymphomas, with increased expression of MYC and BCL2 protein. The overall response rate was 60% for relapsed/refractory non–germinal center double-expressor lymphoma patients treated with ibrutinib.

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Landsburg, Daniel J., Hughes, Mitchell E., Koike, Alexa, Bond, David, Maddocks, Kami J., Guo, Ling, Winter, Allison M., Hill, Brian T., Ondrejka, Sarah L., Hsi, Eric D., Nasta, Sunita D., Svoboda, Jakub, Schuster, Stephen J., Bogusz, Agata M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Stimulus Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6341198/
https://ncbi.nlm.nih.gov/pubmed/30651281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018026401
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados